Annual Drug Patent Expirations for XELJANZ
Xeljanz is a drug marketed by Pfizer and Pf Prism Cv and is included in three NDAs. It is available from two suppliers. There are five patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for XELJANZ.
This drug has one hundred and three patent family members in fifty-four countries.
The generic ingredient in XELJANZ is tofacitinib citrate. Two suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
